Are anti-interferon antibodies the cause of failure in: chronic HCV hepatitis treatment?

Are anti-interferon antibodies the cause of failure in: chronic HCV hepatitis treatment?

A follow-up study was made of 94 chronic hepatitis C patients at a hepatitis clinic in Brazil, after interferon alpha (IFN-alpha) therapy, to determine the influence of anti-interferon antibodies on treatment outcome. Patients diagnosed as having chronic hepatitis C, confirmed by PCR (HCV RNA) and l...

Full description

Bibliographic Details
Main Authors:	Antonio Alci Barone, Rose Aparecida Borges Tosta, Fátima Mitiko Tengan, José Humberto Caetano Marins, Norma de Paula Cavalheiro, Bruno Andrade Cardi
Format:	Article
Language:	English
Published:	Elsevier
Series:	Brazilian Journal of Infectious Diseases
Subjects:	Interferon-alpha antibodies chronic HCV treatment
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702004000100002&lng=en&tlng=en

Similar Items

The influence of HAART on the efficacy and safety of pegylated interferon and ribavirin therapy for the treatment of chronic HCV infection in HIV-positive individuals
by: Vogel M, et al.
Published: (2010-03-01)

Successful treatment of HCV/HBV/HDV-coinfection with pegylated interferon and ribavirin
by: Janine Hartl, et al.
Published: (2012-07-01)

Polineuropatia desmielinizante inflamatória crônica pós-tratamento com interferon peguilado alfa 2b em um paciente co-infectado HIV/HCV: relato de caso Chronic inflammatory demyelinating polyneuropathy after treatment with pegylated interferon alpha 2b in a patient with HIV/HCV coinfection: case report
by: Bil Randerson Bassetti, et al.
Published: (2010-02-01)

Autoanticuerpos en pacientes hematológicos tratados con interferón alfa
by: Antonio A Bencomo Hernández, et al.

Interferon lambda: opportunities, risks and uncertainties in the fight against HCV
by: Stephen M Laidlaw, et al.
Published: (2014-10-01)

Prevalence of Hepatitis C Virus (HCV) Genotypes in Rawalpindi and Islamabad Region
by: Andleeb Afzal
Published: (2017-06-01)

HCV-induced autophagy and innate immunity
by: Jiyoung Lee, et al.
Published: (2024-02-01)

The evolving role of interferons in viral eradication strategies
by: Tomas Doyle
Published: (2016-04-01)

Impact of Interferon-Based Therapy on Hepatitis C-Associated Rheumatic Diseases: A Nationwide Population-Based Cohort Study
by: Jur-Shan Cheng, et al.
Published: (2021-02-01)

Neutralizing activities of caprine antibodies towards conserved regions of the HCV envelope glycoprotein E2
by: El-Shenawy Reem, et al.
Published: (2011-08-01)

Most common HCV genotypes in patients from north-eastern Croatia
by: Magdalena Perić, et al.
Published: (2014-05-01)

Comparative studies in detection of anti-HCV antibodies using Abbott IMx HCV, Serodia-HCV and DETECT-HCVTM
by: Nisarat Apichartpiyakul, et al.
Published: (2010-01-01)

Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study
by: Vincenzo Messina, et al.
Published: (2020-12-01)

Role of IL-28B polymorphisms in virologic response to combined pegylated interferon and ribavirin therapy in genotype 4 chronic HCV infected patients with and without cirrhosis
by: Amira Youssef Shaala, et al.
Published: (2015-09-01)

Developments in the HCV Screening Technologies Based on the Detection of Antigens and Antibodies
by: Shrikant Dashrath Warkad, et al.
Published: (2019-09-01)

HCV carriers with normal aminotransferase levels: “normal” does not always mean “healthy”
by: Claudio Puoti
Published: (2013-04-01)

Production and Characterization of Polyclonal Antibodies Against Interferon Alpha in Mice
by: Mehreen Fatima, et al.
Published: (2021-11-01)

Association of HCV Load and Interferon Therapeutic Response with Gender in Hepatitis C Patients Presenting to a Tertiary Care Health Facility, Rawalpindi
by: Mahnoor Javed Janjua
Published: (2018-11-01)

Interferon α therapy in patients with chronic hepatitis C infection: quality of life and depression
by: Ciro Conversano, et al.
Published: (2015-03-01)

HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients
by: Óscar Brochado, et al.
Published: (2021-03-01)

Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis
by: Nelson Cheinquer, et al.

Shared and Unique Features of Human Interferon-Beta and Interferon-Alpha Subtypes
by: Megen C. Wittling, et al.
Published: (2021-01-01)

Anti-diabetic drugs, insulin and metformin, have no direct interaction with hepatitis C virus infection or anti-viral interferon response
by: Mohamad S. Hakim, et al.
Published: (2014-01-01)

Fast relapse and high drop out rate of 48 weeks daily interferon monotherapy in HIV-infected patients with chronic hepatitis C
by: Patruno Savino FA, et al.
Published: (2002-08-01)

Influência da infecção pregressa pelo vírus da hepatite B na fibrose hepática em portadores de hepatite C crônica: avaliação retrospectiva de uma série de casos Influence of previous hepatitis B virus infection on liver fibrosis in patients with chronic hepatitis C: a retrospective case series evaluation
by: Gaspar Lisboa Neto, et al.
Published: (2010-08-01)

Mechanism of HCV's resistance to IFN-α in cell culture involves expression of functional IFN-α receptor 1
by: Lamaze Christophe, et al.
Published: (2011-07-01)

Feasibility of anti-HCV reflex HCV Ag screening strategy in an HCV endemic community
by: Wei-Ming Chen, et al.
Published: (2021-05-01)

Hematological Side Effects During Combination Therapy With Interferon and Ribavirin In Chronic Hepatitis C
by: Komal Owais
Published: (2015-06-01)

HCV treatment in children and young adults with HIV/HCV co-infection in Europe
by: Anna Turkova, et al.
Published: (2015-07-01)

The humoral immune response to HCV: understanding is key to vaccine development
by: Siobhán B Cashman, et al.
Published: (2014-11-01)

HCV Innate Immune Responses
by: Markus H. Heim
Published: (2009-11-01)

Evaluation of Two-Assay Serological Testing Strategies for Anti-HCV Screening in Italian Populations: A Dual Screening Approach
by: Elena Zocca, et al.
Published: (2024-03-01)

The Role of MicroRNAs in Response to Interferon Treatment of Chronic Hepatitis C patients
by: Eman El-Ahwany, et al.
Published: (2016-02-01)

Type-III interferons and rheumatoid arthritis: Correlation between interferon lambda 1 (interleukin 29) and antimutated citrullinated vimentin antibody levels
by: Diana Castillo-Martínez, et al.
Published: (2017-02-01)

Significance of the interferon (IFN) in the therapy
by: Sabina Mahmutović, et al.
Published: (2004-11-01)

TYROSINE KINASE INHIBITORS AND INTERFERON
by: Maria Dimou, et al.
Published: (2014-01-01)

Transcriptional response to hepatitis C virus infection and interferon‐alpha treatment in the human liver
by: Tujana Boldanova, et al.
Published: (2017-06-01)

Treatment of hepatitis C virus infection: From therapy with interferon to direct-acting antivirals
by: Laura Lopera, et al.
Published: (2023-01-01)

Insights Into Type I and III Interferons in Asthma and Exacerbations
by: Helen E. Rich, et al.
Published: (2020-09-01)

Fibroscan versus liver biopsy in the evaluation of response among the Egyptian HCV infected patients to treatment
by: Sherif El Saadany, et al.
Published: (2016-03-01)